Respiratory Syncytial Virus Infections
Conditions
Brief summary
The purpose of this study was to evaluate the infectivity, safety, and immunogenicity of the recombinant live-attenuated respiratory syncytial virus (RSV) vaccines RSV ΔNS2/Δ1313/I1314L or RSV 276 when delivered as nose drops to RSV-seronegative infants 6 to 24 months of age. This study was a companion study to Center for Immunization Research (CIR) 321.
Detailed description
Human respiratory syncytial virus (RSV) is the most common viral cause of serious acute lower respiratory illness (LRI) in infants and children under 5 years of age worldwide. This study evaluated the infectivity, safety, and immunogenicity of two recombinant live-attenuated RSV vaccines: RSV ΔNS2/Δ1313/I1314L and RSV 276. The vaccines were delivered as nose drops to RSV-seronegative infants 6 to 24 months of age. Participants were randomly assigned to receive a single dose of the RSV ΔNS2/Δ1313/I1314L vaccine, the RSV 276 vaccine, or placebo at study entry (Day 0). Participants could be enrolled in the study outside of RSV season, i.e., between April 1 and October 14 for most sites or-for sites with local RSV seasons that start earlier-as specified on a site-by-site basis in the manual of procedures. Participants remained on study until they completed the post-RSV season visit between April 1 and April 30 in the calendar year following enrollment. Participants' total study duration was between 6 and 13 months, depending on when they enrolled in the study. Participants attended several study visits throughout the study, which included physical examinations, blood collection, nasal washes, and/or nasal adsorption (nasosorption) specimen collection. Participants' parents or guardians were contacted by study staff at various times during the study to monitor participants' health.
Interventions
BIOLOGICALRSV ΔNS2/Δ1313/I1314L
10\^6 plaque-forming units (PFU); administered as nose drops
BIOLOGICALRSV 276
10\^5 PFU; administered as nose drops
BIOLOGICALPlacebo
Isotonic diluent, administered as nose drops
Sponsors
National Institute of Allergy and Infectious Diseases (NIAID)
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)
Eligibility
Sex/Gender
ALL
Age
6 Months to 24 Months
Healthy volunteers
Yes
Inclusion criteria
* In good health based on review of the medical record, history, and physical examination, without evidence of chronic disease. * Parent/guardian willing and able to provide written informed consent as described in the protocol. * Seronegative for RSV antibody, defined as a serum RSV-neutralizing antibody titer less than 1:40 at screening from a sample collected no more than 42 days prior to inoculation. * Growing normally for age (i.e., not downwardly crossing two major centiles on a standard growth chart) in the six months prior to enrollment AND * If less than 1 year of age: current height and weight above the 5th percentile * If 1 year of age or older: current height and weight above the 3rd percentile for age. * Received routine immunizations appropriate for age (as per national Center for Disease Control Advisory Committee on Immunization Practices). * Expected to be available for the duration of the study. * If born to an HIV-infected woman, participant must not have been breastfed and must have documentation of 2 negative HIV nucleic acid (RNA or DNA) test results from samples collected on different dates with both collected when greater than or equal to 4 weeks of age and at least one collected when greater than or equal to 16 weeks of age, and no positive HIV nucleic acid (RNA or DNA) test; or 2 negative HIV antibody tests, both from samples collected at greater than or equal to 24 weeks of age.
Exclusion criteria
* Known or suspected HIV infection or impairment of immunological functions. * Receipt of immunosuppressive therapy, including any systemic, including either nasal or inhaled, corticosteroids within 28 days of enrollment. Note: Cutaneous (topical) steroid treatment is not an exclusion. * Any receipt of bone marrow/solid organ transplant. * Major congenital malformations (such as congenital cleft palate) or cytogenetic abnormalities. * Previous receipt of a licensed or investigational RSV vaccine (or placebo in any International Maternal Pediatric Adolescent AIDS Clinical Trials Network RSV study) or previous receipt of or planned administration of any anti-RSV product (such as ribavirin or RSV IG or RSV mAb). * Any previous anaphylactic reaction. * Any previous vaccine-associated adverse reaction that was Grade 3 or above. Note: if grading is not possible, determine if the reaction was considered severe or life threatening; if so, it is exclusionary. * Any known hypersensitivity to any study product component. * Heart disease. Note: Participants with cardiac abnormalities documented to be clinically insignificant and requiring no treatment may be enrolled. * Lung disease, including any history of reactive airway disease or medically diagnosed wheezing. * Member of a household that contained, or would contain, an infant who is less than 6 months of age at the enrollment date through Day 28. * Member of a household that contained another child/other children who was/were, or was/were scheduled to be, enrolled in IMPAACT 2018 AND the date of enrollment to IMPAACT 2018 would not be concurrent with the other participant(s) living in the household (i.e., all eligible children from the same household must be enrolled on the same date). * Member of a household that contained another child who was, or was scheduled to be, enrolled in another study evaluating an intranasal live-attenuated RSV vaccine, AND there has been or would be an overlap in residency during that other child's participation in the study's Acute Phase (Days 0 to 28). * Member of a household that contained an immunocompromised individual, including, but not limited to: * a person who was greater than or equal to 6 years of age with HIV-related immunodeficiency, defined as having a most recent CD4 T lymphocyte cell count less than 300 cells/mm\^3. CD4 T lymphocyte count must have been measured within 6 months prior to enrollment for individuals with detectable virus or within 12 months prior to enrollment for individuals with undetectable virus, or * a person age 1 year up to less than 6 years with HIV-related immunodeficiency, defined as having a most recent CD4 T lymphocyte cell percentage less than 25 or CD4 T lymphocyte count less than 750 cells/mm\^3 (if both values are available, use the lower of the two). CD4 T lymphocyte parameter must have been measured within the 6 months prior to enrollment; or * a person age less than 1 year with HIV-related immunodeficiency, defined as having a most recent CD4 T lymphocyte cell percentage less than 30 or CD4 T lymphocyte count less than 1000 cells/mm\^3 (if both values are available, use the lower of the two). CD4 T lymphocyte parameter must have been measured within the 6 months prior to enrollment; or * a person who had received chemotherapy within the 12 months prior to enrollment; or * a person receiving immunosuppressant agents; or * a person living with a solid organ or bone marrow transplant. Documenting the verbal report of CD4 T cell lymphocyte count was sufficient if the parent/guardian was confident of history. Individually identifiable information (e.g., name) pertaining to members of the household were not collected or recorded. Confirmatory laboratory tests for members of the household were not ordered or collected. * Attended a daycare facility and shared a room with infants less than 6 months of age, and parent/guardian was unable or unwilling to suspend daycare for 28 days following inoculation. * Any of the following events at the time of enrollment: * fever (rectal temperature of greater than or equal to 100.4°F (38°C)), or * upper respiratory signs or symptoms (rhinorrhea, cough, or pharyngitis) or * nasal congestion significant enough to interfere with successful inoculation, or * otitis media. * Receipt of the following prior to enrollment: * any inactivated vaccine or live-attenuated rotavirus vaccine within the 14 days prior, or * any live vaccine, other than rotavirus vaccine, within the 28 days prior, or * another investigational vaccine or investigational drug within 28 days prior * Scheduled administration of the following after planned inoculation: * inactivated vaccine or live-attenuated rotavirus vaccine within the 14 days after, or * any live vaccine other than rotavirus in the 28 days after, or * another investigational vaccine or investigational drug in the 56 days after * Receipt of immunoglobulin, any antibody products, or any blood products within the past 6 months prior to enrollment. * Receipt of any of the following medications within 3 days prior to study enrollment: * systemic antibacterial, antiviral, antifungal, anti-parasitic, or antituberculous agents, whether for treatment or prophylaxis, or * intranasal medications, or * other prescription medication except as listed below. Permitted concomitant medications (prescription or non-prescription) include nutritional supplements, medications for gastroesophageal reflux, eye drops, and topical medications, including (but not limited to) cutaneous (topical) steroids, topical antibiotics, and topical antifungal agents. * Receipt of salicylate (aspirin) or salicylate-containing products within the 28 days prior to enrollment. * Born at less than 34 weeks gestation. * Born at less than 37 weeks gestation and less than 1 year of age at the time of enrollment. * Current suspected or documented developmental disorder, delay, or other developmental problem. * Any previous receipt of supplemental oxygen therapy in a home setting.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Serum Antibody Responses to RSV F Glycoprotein | Measured at Day 56 | Serum antibody titers to RSV F glycoprotein were assessed by ELISA. |
| Serum RSV-neutralizing Antibody Titers | Measured at Day 56 | Serum RSV-neutralizing antibody titers were assessed by 60% RSV-plaque reduction neutralization titer (RSV-PRNT) assay. |
| Number of Participants With a Greater Than or Equal to 4-fold Rise in Serum Antibody Titers to RSV F Glycoprotein | Measured at Day 0 and Day 56 | Antibodies were assessed by Enzyme-linked Immunosorbent Assay (ELISA). A response was defined as a greater than or equal to 4-fold increase in titer in paired specimens, between pre-inoculation and post-inoculation time points. |
| Number of Participants With Solicited Adverse Events (AEs) by Grade | Measured from Day 0 through Day 28 | Solicited adverse events included fever; otitis media; upper respiratory illness (URI); lower respiratory illness (LRI) and cough (without LRI). The number of participants who experienced solicited adverse events was presented. A participant was only counted once in each solicited AE category, and that is in the line corresponding to the highest grade adverse event they had in that category. These events were graded (Grade 1-mild to Grade 4-life-threatening) following protocol-defined grading system outlined in Table 5 and Table 6 in the protocol document. |
| Number of Participants With Unsolicited AEs | Measured from Day 0 through Day 28 | Unsolicited adverse events were other events, not included in the solicited AEs. The number of participants who experienced solicited adverse events was presented. A participant was only counted once in each unsolicited AE category, and that is in the line corresponding to the highest grade adverse event they had in that category. AE grading (Grade 1- mild to Grade 4-life-threatening) was done by Division of AIDS (DAIDS) AE Grading table v2.0 (see References). |
| Number of Participants With Serious Adverse Events (SAEs) | Measured from Day 0 through Day 56 | A Serious Adverse Event (SAE) is an AE, whether considered related to the study product or not, that: * Results in death during the period of protocol-defined surveillance; * Is life threatening: defined as an event in which the patient was at immediate risk of death at the time of the event; it does not refer to an event that hypothetically might have caused death were it more severe; * Requires inpatient hospitalization (or prolongation of existing hospitalization): defined as at least an overnight stay in the hospital or emergency ward for treatment that would have been inappropriate if administered in the outpatient setting; * Results in a persistent or significant disability/incapacity; * Is a congenital anomaly or birth defect, OR * Is an important medical event that may not be immediately life threatening or result in death or hospitalization but may jeopardize the patient or may require intervention to prevent one of the outcomes listed above. |
| Number of Participants Infected With RSV Vaccine Virus | Measured at Days 0, 3, 5, 7, 10, 12, 14, 17, and 28 for nasal washes, and at Days 0, 56 for serum RSV-neutralizing antibodies | Defined as 1) vaccine virus identified in a nasal wash from Study Day 0-28 (a binary outcome based on nasal washes); and/or 2) greater than or equal to 4-fold rise in RSV serum neutralizing antibody titer and/or serum enzyme-linked immunosorbent assay (ELISA) titer to the RSV F protein from study entry to Study Day 56 |
| Peak Titer of Vaccine Virus Shed | Measured at Days 0, 3, 5, 7, 10, 12, 14, 17, and 28 | This is the highest value per participant of the titer of vaccine virus shed. It was measured by culture. Only participants who met the definition of infection with vaccine virus were included. |
| Duration of Virus Shedding in Nasal Washes | Measured at Days 0, 3, 5, 7, 10, 12, 14, 17, and 28. Last day positive is reported. | Determined separately by a) culture and b) reverse transcription polymerase chain reaction (RT-PCR) |
| Number of Participants With a Greater Than or Equal to 4-fold Rise in Serum RSV-neutralizing Antibody Titers | Measured at Day 0 and Day 56 | Antibody responses were defined as a greater than or equal to 4-fold increase in titer in paired specimens, between pre-inoculation and post-inoculation time points. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Magnitude of Serum RSV-neutralizing Antibody Responses in the Vaccine and Placebo Recipients Who Experienced Natural Infection With wt RSV During the Subsequent RSV Season. | Measured through participant's last study visit, up to a total of 6 to 10 months depending on when participants enrolled in the study | Only participants who had RSV detected in nasal washes or a greater than or equal to 4-fold rise in serum antibodies during the subsequent RSV season were included. RSV-neutralizing antibody titers were measured pre- and post-RSV surveillance season subsequent to the time of the inoculation. |
| Number of Participants Who Had RSV-associated Symptomatic, Medically Attended Respiratory and Febrile Illness, by Grade, Among Those Who Experienced Natural Infection With wt RSV During the Subsequent RSV Season | Measured through participant's last study visit, up to a total of 6 to 10 months depending on when participants enrolled in the study | The number of participants who had RSV-associated, symptomatic, medically attended respiratory and febrile illness (MAARI) among those who had indicators of natural infection with wt RSV were presented. Natural infection with wt RSV during the RSV season surveillance was defined as having either RSV detected in nasal washes collected during illness visits for MAARI events or a \> 4-fold rise in serum antibodies from pre- to post-RSV season in the absence of RSV-associated medical events. A participant was only counted once in each MAARI category, and that was in the line corresponding to the highest grade adverse event they had in that category. These events were graded (Grade 1-mild to Grade 4-life-threatening) following protocol-defined grading system outlined in Table 5 and Table 6 in the protocol document. |
Countries
United States
Participant flow
Recruitment details
Recruitment period was from September 2017 to October 2019. Participants were recruited from 12 medical clinics all in the United States.
Participants by arm
| Arm | Count |
|---|---|
| RSV ΔNS2/Δ1313/I1314L Vaccine Participants received a single dose of the RSV ΔNS2/Δ1313/I1314L vaccine at study entry (Day 0).
RSV ΔNS2/Δ1313/I1314L: 10\^6 plaque-forming units (PFU); administered as nose drops | 25 |
| RSV 276 Vaccine Participants received a single dose of the RSV 276 vaccine at study entry (Day 0).
RSV 276: 10\^5 PFU; administered as nose drops | 25 |
| Placebo Participants received a single dose of placebo at study entry (Day 0).
Placebo: Isotonic diluent, administered as nose drops | 12 |
| Total | 62 |
Withdrawals & dropouts
| Period | Reason | FG000 | FG001 | FG002 |
|---|---|---|---|---|
| Overall Study | Child Wheezed (no treatment) | 0 | 1 | 0 |
| Overall Study | No post RSV season visit due to COVID | 3 | 3 | 2 |
| Overall Study | Not able to get to clinic | 0 | 0 | 1 |
| Overall Study | Unable to receive treatment in time (no treatment) | 0 | 0 | 1 |
| Overall Study | Withdrawal by Subject | 1 | 0 | 0 |
Baseline characteristics
| Characteristic | RSV ΔNS2/Δ1313/I1314L Vaccine | Total | Placebo | RSV 276 Vaccine |
|---|---|---|---|---|
| Age, Continuous | 13 months | 12.5 months | 9 months | 14 months |
| Ethnicity (NIH/OMB) Hispanic or Latino | 9 Participants | 21 Participants | 3 Participants | 9 Participants |
| Ethnicity (NIH/OMB) Not Hispanic or Latino | 15 Participants | 40 Participants | 9 Participants | 16 Participants |
| Ethnicity (NIH/OMB) Unknown or Not Reported | 1 Participants | 1 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) American Indian or Alaska Native | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Asian | 0 Participants | 2 Participants | 0 Participants | 2 Participants |
| Race (NIH/OMB) Black or African American | 7 Participants | 20 Participants | 6 Participants | 7 Participants |
| Race (NIH/OMB) More than one race | 2 Participants | 4 Participants | 0 Participants | 2 Participants |
| Race (NIH/OMB) Native Hawaiian or Other Pacific Islander | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Unknown or Not Reported | 1 Participants | 1 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) White | 15 Participants | 35 Participants | 6 Participants | 14 Participants |
| Region of Enrollment United States | 25 participants | 62 participants | 12 participants | 25 participants |
| Serum RSV-neutralizing antibody titers | 2.3 Log 2 titers | 2.3 Log 2 titers | 2.3 Log 2 titers | 2.3 Log 2 titers |
| Sex: Female, Male Female | 13 Participants | 29 Participants | 9 Participants | 7 Participants |
| Sex: Female, Male Male | 12 Participants | 33 Participants | 3 Participants | 18 Participants |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk | EG002 affected / at risk |
|---|---|---|---|
| deaths Total, all-cause mortality | 0 / 25 | 0 / 25 | 0 / 12 |
| other Total, other adverse events | 21 / 25 | 21 / 25 | 8 / 12 |
| serious Total, serious adverse events | 1 / 25 | 0 / 25 | 0 / 12 |
Outcome results
Primary
Duration of Virus Shedding in Nasal Washes
Determined separately by a) culture and b) reverse transcription polymerase chain reaction (RT-PCR)
Time frame: Measured at Days 0, 3, 5, 7, 10, 12, 14, 17, and 28. Last day positive is reported.
Population: Only participants who met the definition of infection with vaccine virus were included.
| Arm | Measure | Group | Value (MEDIAN) |
|---|---|---|---|
| RSV ΔNS2/Δ1313/I1314L Vaccine | Duration of Virus Shedding in Nasal Washes | Culture positive | 10 days |
| RSV ΔNS2/Δ1313/I1314L Vaccine | Duration of Virus Shedding in Nasal Washes | RT-PCR positive | 13 days |
| RSV 276 Vaccine | Duration of Virus Shedding in Nasal Washes | Culture positive | 10 days |
| RSV 276 Vaccine | Duration of Virus Shedding in Nasal Washes | RT-PCR positive | 14 days |
Primary
Number of Participants Infected With RSV Vaccine Virus
Defined as 1) vaccine virus identified in a nasal wash from Study Day 0-28 (a binary outcome based on nasal washes); and/or 2) greater than or equal to 4-fold rise in RSV serum neutralizing antibody titer and/or serum enzyme-linked immunosorbent assay (ELISA) titer to the RSV F protein from study entry to Study Day 56
Time frame: Measured at Days 0, 3, 5, 7, 10, 12, 14, 17, and 28 for nasal washes, and at Days 0, 56 for serum RSV-neutralizing antibodies
Population: Study participants who received inoculation and were followed on study past Day 0 were included. One child from a set of twins was randomly selected and excluded from the analysis.
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| RSV ΔNS2/Δ1313/I1314L Vaccine | Number of Participants Infected With RSV Vaccine Virus | 22 Participants |
| RSV 276 Vaccine | Number of Participants Infected With RSV Vaccine Virus | 23 Participants |
| Placebo | Number of Participants Infected With RSV Vaccine Virus | 0 Participants |
90% CI: [72, 97]
90% CI: [82, 100]
90% CI: [0, 22]
Primary
Number of Participants With a Greater Than or Equal to 4-fold Rise in Serum Antibody Titers to RSV F Glycoprotein
Antibodies were assessed by Enzyme-linked Immunosorbent Assay (ELISA). A response was defined as a greater than or equal to 4-fold increase in titer in paired specimens, between pre-inoculation and post-inoculation time points.
Time frame: Measured at Day 0 and Day 56
Population: Study participants who received inoculation and were followed on study past Day 0 were included. One child from a set of twins was randomly selected and excluded from the analysis.
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| RSV ΔNS2/Δ1313/I1314L Vaccine | Number of Participants With a Greater Than or Equal to 4-fold Rise in Serum Antibody Titers to RSV F Glycoprotein | 15 Participants |
| RSV 276 Vaccine | Number of Participants With a Greater Than or Equal to 4-fold Rise in Serum Antibody Titers to RSV F Glycoprotein | 22 Participants |
| Placebo | Number of Participants With a Greater Than or Equal to 4-fold Rise in Serum Antibody Titers to RSV F Glycoprotein | 0 Participants |
90% CI: [42, 76]
90% CI: [76, 98]
90% CI: [0, 22]
p-value: <0.01Fisher Exact
p-value: <0.01Fisher Exact
Primary
Number of Participants With a Greater Than or Equal to 4-fold Rise in Serum RSV-neutralizing Antibody Titers
Antibody responses were defined as a greater than or equal to 4-fold increase in titer in paired specimens, between pre-inoculation and post-inoculation time points.
Time frame: Measured at Day 0 and Day 56
Population: Study participants who received inoculation and were followed on study past Day 0 were included. One child from a set of twins was randomly selected and excluded from the analysis.
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| RSV ΔNS2/Δ1313/I1314L Vaccine | Number of Participants With a Greater Than or Equal to 4-fold Rise in Serum RSV-neutralizing Antibody Titers | 15 Participants |
| RSV 276 Vaccine | Number of Participants With a Greater Than or Equal to 4-fold Rise in Serum RSV-neutralizing Antibody Titers | 22 Participants |
| Placebo | Number of Participants With a Greater Than or Equal to 4-fold Rise in Serum RSV-neutralizing Antibody Titers | 0 Participants |
90% CI: [42, 76]
90% CI: [76, 98]
90% CI: [0, 22]
p-value: <0.01Fisher Exact
p-value: <0.01Fisher Exact
Primary
Number of Participants With Serious Adverse Events (SAEs)
A Serious Adverse Event (SAE) is an AE, whether considered related to the study product or not, that: * Results in death during the period of protocol-defined surveillance; * Is life threatening: defined as an event in which the patient was at immediate risk of death at the time of the event; it does not refer to an event that hypothetically might have caused death were it more severe; * Requires inpatient hospitalization (or prolongation of existing hospitalization): defined as at least an overnight stay in the hospital or emergency ward for treatment that would have been inappropriate if administered in the outpatient setting; * Results in a persistent or significant disability/incapacity; * Is a congenital anomaly or birth defect, OR * Is an important medical event that may not be immediately life threatening or result in death or hospitalization but may jeopardize the patient or may require intervention to prevent one of the outcomes listed above.
Time frame: Measured from Day 0 through Day 56
Population: Study participants who received inoculation and were followed on study past Day 0 were included.
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| RSV ΔNS2/Δ1313/I1314L Vaccine | Number of Participants With Serious Adverse Events (SAEs) | 0 Participants |
| RSV 276 Vaccine | Number of Participants With Serious Adverse Events (SAEs) | 0 Participants |
| Placebo | Number of Participants With Serious Adverse Events (SAEs) | 0 Participants |
Primary
Number of Participants With Solicited Adverse Events (AEs) by Grade
Solicited adverse events included fever; otitis media; upper respiratory illness (URI); lower respiratory illness (LRI) and cough (without LRI). The number of participants who experienced solicited adverse events was presented. A participant was only counted once in each solicited AE category, and that is in the line corresponding to the highest grade adverse event they had in that category. These events were graded (Grade 1-mild to Grade 4-life-threatening) following protocol-defined grading system outlined in Table 5 and Table 6 in the protocol document.
Time frame: Measured from Day 0 through Day 28
Population: Study participants who received inoculation and were followed on study past Day 0 were included.
| Arm | Measure | Group | Category | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|---|
| RSV ΔNS2/Δ1313/I1314L Vaccine | Number of Participants With Solicited Adverse Events (AEs) by Grade | LRI in the absence of RSV shedding | Did not have this AE | 25 Participants |
| RSV ΔNS2/Δ1313/I1314L Vaccine | Number of Participants With Solicited Adverse Events (AEs) by Grade | Upper Respiratory Illness (URI) | Did not have this AE | 9 Participants |
| RSV ΔNS2/Δ1313/I1314L Vaccine | Number of Participants With Solicited Adverse Events (AEs) by Grade | Cough, without LRI | Grade 2 | 0 Participants |
| RSV ΔNS2/Δ1313/I1314L Vaccine | Number of Participants With Solicited Adverse Events (AEs) by Grade | Lower Respiratory Illness (LRI) with RSV shedding | Grade 4 | 0 Participants |
| RSV ΔNS2/Δ1313/I1314L Vaccine | Number of Participants With Solicited Adverse Events (AEs) by Grade | Upper Respiratory Illness (URI) | Grade 1 | 16 Participants |
| RSV ΔNS2/Δ1313/I1314L Vaccine | Number of Participants With Solicited Adverse Events (AEs) by Grade | Cough, without LRI | Grade 1 | 3 Participants |
| RSV ΔNS2/Δ1313/I1314L Vaccine | Number of Participants With Solicited Adverse Events (AEs) by Grade | Lower Respiratory Illness (LRI) with RSV shedding | Grade 3 | 0 Participants |
| RSV ΔNS2/Δ1313/I1314L Vaccine | Number of Participants With Solicited Adverse Events (AEs) by Grade | Upper Respiratory Illness (URI) | Grade 2 | 0 Participants |
| RSV ΔNS2/Δ1313/I1314L Vaccine | Number of Participants With Solicited Adverse Events (AEs) by Grade | Fever | Grade 4 | 0 Participants |
| RSV ΔNS2/Δ1313/I1314L Vaccine | Number of Participants With Solicited Adverse Events (AEs) by Grade | Lower Respiratory Illness (LRI) with RSV shedding | Grade 2 | 0 Participants |
| RSV ΔNS2/Δ1313/I1314L Vaccine | Number of Participants With Solicited Adverse Events (AEs) by Grade | Upper Respiratory Illness (URI) | Grade 3 | 0 Participants |
| RSV ΔNS2/Δ1313/I1314L Vaccine | Number of Participants With Solicited Adverse Events (AEs) by Grade | Fever | Did not have this AE | 21 Participants |
| RSV ΔNS2/Δ1313/I1314L Vaccine | Number of Participants With Solicited Adverse Events (AEs) by Grade | Lower Respiratory Illness (LRI) with RSV shedding | Grade 1 | 0 Participants |
| RSV ΔNS2/Δ1313/I1314L Vaccine | Number of Participants With Solicited Adverse Events (AEs) by Grade | Cough, without LRI | Did not have this AE | 22 Participants |
| RSV ΔNS2/Δ1313/I1314L Vaccine | Number of Participants With Solicited Adverse Events (AEs) by Grade | Upper Respiratory Illness (URI) | Grade 4 | 0 Participants |
| RSV ΔNS2/Δ1313/I1314L Vaccine | Number of Participants With Solicited Adverse Events (AEs) by Grade | Otitis Media | Did not have this AE | 24 Participants |
| RSV ΔNS2/Δ1313/I1314L Vaccine | Number of Participants With Solicited Adverse Events (AEs) by Grade | Lower Respiratory Illness (LRI) with RSV shedding | Did not have this AE | 25 Participants |
| RSV ΔNS2/Δ1313/I1314L Vaccine | Number of Participants With Solicited Adverse Events (AEs) by Grade | Fever | Grade 2 | 1 Participants |
| RSV ΔNS2/Δ1313/I1314L Vaccine | Number of Participants With Solicited Adverse Events (AEs) by Grade | LRI in the absence of RSV shedding | Grade 4 | 0 Participants |
| RSV ΔNS2/Δ1313/I1314L Vaccine | Number of Participants With Solicited Adverse Events (AEs) by Grade | Otitis Media | Grade 1 | 0 Participants |
| RSV ΔNS2/Δ1313/I1314L Vaccine | Number of Participants With Solicited Adverse Events (AEs) by Grade | Fever | Grade 1 | 1 Participants |
| RSV ΔNS2/Δ1313/I1314L Vaccine | Number of Participants With Solicited Adverse Events (AEs) by Grade | LRI in the absence of RSV shedding | Grade 3 | 0 Participants |
| RSV ΔNS2/Δ1313/I1314L Vaccine | Number of Participants With Solicited Adverse Events (AEs) by Grade | Otitis Media | Grade 2 | 1 Participants |
| RSV ΔNS2/Δ1313/I1314L Vaccine | Number of Participants With Solicited Adverse Events (AEs) by Grade | Cough, without LRI | Grade 4 | 0 Participants |
| RSV ΔNS2/Δ1313/I1314L Vaccine | Number of Participants With Solicited Adverse Events (AEs) by Grade | LRI in the absence of RSV shedding | Grade 2 | 0 Participants |
| RSV ΔNS2/Δ1313/I1314L Vaccine | Number of Participants With Solicited Adverse Events (AEs) by Grade | Otitis Media | Grade 3 | 0 Participants |
| RSV ΔNS2/Δ1313/I1314L Vaccine | Number of Participants With Solicited Adverse Events (AEs) by Grade | Cough, without LRI | Grade 3 | 0 Participants |
| RSV ΔNS2/Δ1313/I1314L Vaccine | Number of Participants With Solicited Adverse Events (AEs) by Grade | LRI in the absence of RSV shedding | Grade 1 | 0 Participants |
| RSV ΔNS2/Δ1313/I1314L Vaccine | Number of Participants With Solicited Adverse Events (AEs) by Grade | Otitis Media | Grade 4 | 0 Participants |
| RSV ΔNS2/Δ1313/I1314L Vaccine | Number of Participants With Solicited Adverse Events (AEs) by Grade | Fever | Grade 3 | 2 Participants |
| RSV 276 Vaccine | Number of Participants With Solicited Adverse Events (AEs) by Grade | Fever | Grade 3 | 1 Participants |
| RSV 276 Vaccine | Number of Participants With Solicited Adverse Events (AEs) by Grade | Cough, without LRI | Grade 3 | 0 Participants |
| RSV 276 Vaccine | Number of Participants With Solicited Adverse Events (AEs) by Grade | Fever | Grade 1 | 0 Participants |
| RSV 276 Vaccine | Number of Participants With Solicited Adverse Events (AEs) by Grade | Fever | Did not have this AE | 22 Participants |
| RSV 276 Vaccine | Number of Participants With Solicited Adverse Events (AEs) by Grade | Fever | Grade 2 | 2 Participants |
| RSV 276 Vaccine | Number of Participants With Solicited Adverse Events (AEs) by Grade | Fever | Grade 4 | 0 Participants |
| RSV 276 Vaccine | Number of Participants With Solicited Adverse Events (AEs) by Grade | Otitis Media | Did not have this AE | 23 Participants |
| RSV 276 Vaccine | Number of Participants With Solicited Adverse Events (AEs) by Grade | Otitis Media | Grade 1 | 0 Participants |
| RSV 276 Vaccine | Number of Participants With Solicited Adverse Events (AEs) by Grade | Otitis Media | Grade 2 | 2 Participants |
| RSV 276 Vaccine | Number of Participants With Solicited Adverse Events (AEs) by Grade | Otitis Media | Grade 3 | 0 Participants |
| RSV 276 Vaccine | Number of Participants With Solicited Adverse Events (AEs) by Grade | Otitis Media | Grade 4 | 0 Participants |
| RSV 276 Vaccine | Number of Participants With Solicited Adverse Events (AEs) by Grade | Upper Respiratory Illness (URI) | Did not have this AE | 7 Participants |
| RSV 276 Vaccine | Number of Participants With Solicited Adverse Events (AEs) by Grade | Upper Respiratory Illness (URI) | Grade 1 | 16 Participants |
| RSV 276 Vaccine | Number of Participants With Solicited Adverse Events (AEs) by Grade | Upper Respiratory Illness (URI) | Grade 2 | 2 Participants |
| RSV 276 Vaccine | Number of Participants With Solicited Adverse Events (AEs) by Grade | Upper Respiratory Illness (URI) | Grade 3 | 0 Participants |
| RSV 276 Vaccine | Number of Participants With Solicited Adverse Events (AEs) by Grade | Cough, without LRI | Grade 1 | 11 Participants |
| RSV 276 Vaccine | Number of Participants With Solicited Adverse Events (AEs) by Grade | Upper Respiratory Illness (URI) | Grade 4 | 0 Participants |
| RSV 276 Vaccine | Number of Participants With Solicited Adverse Events (AEs) by Grade | Lower Respiratory Illness (LRI) with RSV shedding | Did not have this AE | 25 Participants |
| RSV 276 Vaccine | Number of Participants With Solicited Adverse Events (AEs) by Grade | Lower Respiratory Illness (LRI) with RSV shedding | Grade 1 | 0 Participants |
| RSV 276 Vaccine | Number of Participants With Solicited Adverse Events (AEs) by Grade | Lower Respiratory Illness (LRI) with RSV shedding | Grade 2 | 0 Participants |
| RSV 276 Vaccine | Number of Participants With Solicited Adverse Events (AEs) by Grade | Lower Respiratory Illness (LRI) with RSV shedding | Grade 3 | 0 Participants |
| RSV 276 Vaccine | Number of Participants With Solicited Adverse Events (AEs) by Grade | Lower Respiratory Illness (LRI) with RSV shedding | Grade 4 | 0 Participants |
| RSV 276 Vaccine | Number of Participants With Solicited Adverse Events (AEs) by Grade | LRI in the absence of RSV shedding | Did not have this AE | 25 Participants |
| RSV 276 Vaccine | Number of Participants With Solicited Adverse Events (AEs) by Grade | LRI in the absence of RSV shedding | Grade 1 | 0 Participants |
| RSV 276 Vaccine | Number of Participants With Solicited Adverse Events (AEs) by Grade | LRI in the absence of RSV shedding | Grade 2 | 0 Participants |
| RSV 276 Vaccine | Number of Participants With Solicited Adverse Events (AEs) by Grade | LRI in the absence of RSV shedding | Grade 3 | 0 Participants |
| RSV 276 Vaccine | Number of Participants With Solicited Adverse Events (AEs) by Grade | LRI in the absence of RSV shedding | Grade 4 | 0 Participants |
| RSV 276 Vaccine | Number of Participants With Solicited Adverse Events (AEs) by Grade | Cough, without LRI | Did not have this AE | 13 Participants |
| RSV 276 Vaccine | Number of Participants With Solicited Adverse Events (AEs) by Grade | Cough, without LRI | Grade 2 | 1 Participants |
| RSV 276 Vaccine | Number of Participants With Solicited Adverse Events (AEs) by Grade | Cough, without LRI | Grade 4 | 0 Participants |
| Placebo | Number of Participants With Solicited Adverse Events (AEs) by Grade | Cough, without LRI | Grade 1 | 1 Participants |
| Placebo | Number of Participants With Solicited Adverse Events (AEs) by Grade | Lower Respiratory Illness (LRI) with RSV shedding | Grade 4 | 0 Participants |
| Placebo | Number of Participants With Solicited Adverse Events (AEs) by Grade | Otitis Media | Grade 4 | 0 Participants |
| Placebo | Number of Participants With Solicited Adverse Events (AEs) by Grade | Fever | Did not have this AE | 11 Participants |
| Placebo | Number of Participants With Solicited Adverse Events (AEs) by Grade | LRI in the absence of RSV shedding | Did not have this AE | 12 Participants |
| Placebo | Number of Participants With Solicited Adverse Events (AEs) by Grade | Otitis Media | Grade 3 | 0 Participants |
| Placebo | Number of Participants With Solicited Adverse Events (AEs) by Grade | Cough, without LRI | Grade 4 | 0 Participants |
| Placebo | Number of Participants With Solicited Adverse Events (AEs) by Grade | LRI in the absence of RSV shedding | Grade 1 | 0 Participants |
| Placebo | Number of Participants With Solicited Adverse Events (AEs) by Grade | Otitis Media | Grade 2 | 0 Participants |
| Placebo | Number of Participants With Solicited Adverse Events (AEs) by Grade | Cough, without LRI | Grade 2 | 1 Participants |
| Placebo | Number of Participants With Solicited Adverse Events (AEs) by Grade | LRI in the absence of RSV shedding | Grade 2 | 0 Participants |
| Placebo | Number of Participants With Solicited Adverse Events (AEs) by Grade | Otitis Media | Grade 1 | 0 Participants |
| Placebo | Number of Participants With Solicited Adverse Events (AEs) by Grade | Fever | Grade 2 | 1 Participants |
| Placebo | Number of Participants With Solicited Adverse Events (AEs) by Grade | LRI in the absence of RSV shedding | Grade 3 | 0 Participants |
| Placebo | Number of Participants With Solicited Adverse Events (AEs) by Grade | Otitis Media | Did not have this AE | 12 Participants |
| Placebo | Number of Participants With Solicited Adverse Events (AEs) by Grade | Cough, without LRI | Grade 3 | 0 Participants |
| Placebo | Number of Participants With Solicited Adverse Events (AEs) by Grade | LRI in the absence of RSV shedding | Grade 4 | 0 Participants |
| Placebo | Number of Participants With Solicited Adverse Events (AEs) by Grade | Upper Respiratory Illness (URI) | Grade 4 | 0 Participants |
| Placebo | Number of Participants With Solicited Adverse Events (AEs) by Grade | Fever | Grade 4 | 0 Participants |
| Placebo | Number of Participants With Solicited Adverse Events (AEs) by Grade | Lower Respiratory Illness (LRI) with RSV shedding | Did not have this AE | 12 Participants |
| Placebo | Number of Participants With Solicited Adverse Events (AEs) by Grade | Upper Respiratory Illness (URI) | Grade 3 | 0 Participants |
| Placebo | Number of Participants With Solicited Adverse Events (AEs) by Grade | Fever | Grade 1 | 0 Participants |
| Placebo | Number of Participants With Solicited Adverse Events (AEs) by Grade | Lower Respiratory Illness (LRI) with RSV shedding | Grade 1 | 0 Participants |
| Placebo | Number of Participants With Solicited Adverse Events (AEs) by Grade | Upper Respiratory Illness (URI) | Grade 2 | 0 Participants |
| Placebo | Number of Participants With Solicited Adverse Events (AEs) by Grade | Cough, without LRI | Did not have this AE | 10 Participants |
| Placebo | Number of Participants With Solicited Adverse Events (AEs) by Grade | Lower Respiratory Illness (LRI) with RSV shedding | Grade 2 | 0 Participants |
| Placebo | Number of Participants With Solicited Adverse Events (AEs) by Grade | Upper Respiratory Illness (URI) | Grade 1 | 5 Participants |
| Placebo | Number of Participants With Solicited Adverse Events (AEs) by Grade | Fever | Grade 3 | 0 Participants |
| Placebo | Number of Participants With Solicited Adverse Events (AEs) by Grade | Lower Respiratory Illness (LRI) with RSV shedding | Grade 3 | 0 Participants |
| Placebo | Number of Participants With Solicited Adverse Events (AEs) by Grade | Upper Respiratory Illness (URI) | Did not have this AE | 7 Participants |
90% CI: [46, 80]
90% CI: [67, 94]
90% CI: [32, 82]
Primary
Number of Participants With Unsolicited AEs
Unsolicited adverse events were other events, not included in the solicited AEs. The number of participants who experienced solicited adverse events was presented. A participant was only counted once in each unsolicited AE category, and that is in the line corresponding to the highest grade adverse event they had in that category. AE grading (Grade 1- mild to Grade 4-life-threatening) was done by Division of AIDS (DAIDS) AE Grading table v2.0 (see References).
Time frame: Measured from Day 0 through Day 28
Population: Study participants who received inoculation and were followed on study past Day 0 were included.
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| RSV ΔNS2/Δ1313/I1314L Vaccine | Number of Participants With Unsolicited AEs | 9 Participants |
| RSV 276 Vaccine | Number of Participants With Unsolicited AEs | 13 Participants |
| Placebo | Number of Participants With Unsolicited AEs | 5 Participants |
90% CI: [20, 54]
90% CI: [34, 69]
90% CI: [18, 68]
Primary
Peak Titer of Vaccine Virus Shed
This is the highest value per participant of the titer of vaccine virus shed. It was measured by culture. Only participants who met the definition of infection with vaccine virus were included.
Time frame: Measured at Days 0, 3, 5, 7, 10, 12, 14, 17, and 28
Population: Only participants who met the definition of infection with vaccine virus were included.
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| RSV ΔNS2/Δ1313/I1314L Vaccine | Peak Titer of Vaccine Virus Shed | 3.1 log 10 PFU/mL |
| RSV 276 Vaccine | Peak Titer of Vaccine Virus Shed | 3.2 log 10 PFU/mL |
Primary
Serum Antibody Responses to RSV F Glycoprotein
Serum antibody titers to RSV F glycoprotein were assessed by ELISA.
Time frame: Measured at Day 56
Population: Study participants who received inoculation and were followed on study past Day 0 were included. One child from a set of twins was randomly selected and excluded from the analysis.
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| RSV ΔNS2/Δ1313/I1314L Vaccine | Serum Antibody Responses to RSV F Glycoprotein | 10.4 log 2 titers |
| RSV 276 Vaccine | Serum Antibody Responses to RSV F Glycoprotein | 12.6 log 2 titers |
| Placebo | Serum Antibody Responses to RSV F Glycoprotein | 6.4 log 2 titers |
p-value: <0.01Wilcoxon (Mann-Whitney)
p-value: <0.01Wilcoxon (Mann-Whitney)
Primary
Serum RSV-neutralizing Antibody Titers
Serum RSV-neutralizing antibody titers were assessed by 60% RSV-plaque reduction neutralization titer (RSV-PRNT) assay.
Time frame: Measured at Day 56
Population: Study participants who received inoculation and were followed on study past Day 0 were included. One child from a set of twins was randomly selected and excluded from the analysis.
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| RSV ΔNS2/Δ1313/I1314L Vaccine | Serum RSV-neutralizing Antibody Titers | 5.1 log 2 titers |
| RSV 276 Vaccine | Serum RSV-neutralizing Antibody Titers | 6.7 log 2 titers |
| Placebo | Serum RSV-neutralizing Antibody Titers | 2.3 log 2 titers |
p-value: <0.01Wilcoxon (Mann-Whitney)
p-value: <0.01Wilcoxon (Mann-Whitney)
Secondary
Magnitude of Serum RSV-neutralizing Antibody Responses in the Vaccine and Placebo Recipients Who Experienced Natural Infection With wt RSV During the Subsequent RSV Season.
Only participants who had RSV detected in nasal washes or a greater than or equal to 4-fold rise in serum antibodies during the subsequent RSV season were included. RSV-neutralizing antibody titers were measured pre- and post-RSV surveillance season subsequent to the time of the inoculation.
Time frame: Measured through participant's last study visit, up to a total of 6 to 10 months depending on when participants enrolled in the study
Population: Only participants who had RSV detected in nasal washes or a greater than or equal to 4-fold rise in serum antibodies during the subsequent RSV season were included. One child from a set of twins was randomly selected and excluded from the analysis.
| Arm | Measure | Group | Value (MEDIAN) |
|---|---|---|---|
| RSV ΔNS2/Δ1313/I1314L Vaccine | Magnitude of Serum RSV-neutralizing Antibody Responses in the Vaccine and Placebo Recipients Who Experienced Natural Infection With wt RSV During the Subsequent RSV Season. | Pre-RSV surveillance | 4.0 log 2 titers |
| RSV ΔNS2/Δ1313/I1314L Vaccine | Magnitude of Serum RSV-neutralizing Antibody Responses in the Vaccine and Placebo Recipients Who Experienced Natural Infection With wt RSV During the Subsequent RSV Season. | Post-RSV surveillance | 10.1 log 2 titers |
| RSV 276 Vaccine | Magnitude of Serum RSV-neutralizing Antibody Responses in the Vaccine and Placebo Recipients Who Experienced Natural Infection With wt RSV During the Subsequent RSV Season. | Pre-RSV surveillance | 6.1 log 2 titers |
| RSV 276 Vaccine | Magnitude of Serum RSV-neutralizing Antibody Responses in the Vaccine and Placebo Recipients Who Experienced Natural Infection With wt RSV During the Subsequent RSV Season. | Post-RSV surveillance | 10.6 log 2 titers |
| Placebo | Magnitude of Serum RSV-neutralizing Antibody Responses in the Vaccine and Placebo Recipients Who Experienced Natural Infection With wt RSV During the Subsequent RSV Season. | Pre-RSV surveillance | 2.3 log 2 titers |
| Placebo | Magnitude of Serum RSV-neutralizing Antibody Responses in the Vaccine and Placebo Recipients Who Experienced Natural Infection With wt RSV During the Subsequent RSV Season. | Post-RSV surveillance | 5.9 log 2 titers |
Secondary
Number of Participants Who Had RSV-associated Symptomatic, Medically Attended Respiratory and Febrile Illness, by Grade, Among Those Who Experienced Natural Infection With wt RSV During the Subsequent RSV Season
The number of participants who had RSV-associated, symptomatic, medically attended respiratory and febrile illness (MAARI) among those who had indicators of natural infection with wt RSV were presented. Natural infection with wt RSV during the RSV season surveillance was defined as having either RSV detected in nasal washes collected during illness visits for MAARI events or a \> 4-fold rise in serum antibodies from pre- to post-RSV season in the absence of RSV-associated medical events. A participant was only counted once in each MAARI category, and that was in the line corresponding to the highest grade adverse event they had in that category. These events were graded (Grade 1-mild to Grade 4-life-threatening) following protocol-defined grading system outlined in Table 5 and Table 6 in the protocol document.
Time frame: Measured through participant's last study visit, up to a total of 6 to 10 months depending on when participants enrolled in the study
Population: Only participants who had RSV detected in nasal washes or had greater than or equal to 4 fold rise in serum antibodies from pre- to post-RSV season in the absence of RSV-associated medical events were included.
| Arm | Measure | Group | Category | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|---|
| RSV ΔNS2/Δ1313/I1314L Vaccine | Number of Participants Who Had RSV-associated Symptomatic, Medically Attended Respiratory and Febrile Illness, by Grade, Among Those Who Experienced Natural Infection With wt RSV During the Subsequent RSV Season | Medically Attended URI | Grade 4 | 0 Participants |
| RSV ΔNS2/Δ1313/I1314L Vaccine | Number of Participants Who Had RSV-associated Symptomatic, Medically Attended Respiratory and Febrile Illness, by Grade, Among Those Who Experienced Natural Infection With wt RSV During the Subsequent RSV Season | Medically Attended Otitis Media | Grade 2 | 2 Participants |
| RSV ΔNS2/Δ1313/I1314L Vaccine | Number of Participants Who Had RSV-associated Symptomatic, Medically Attended Respiratory and Febrile Illness, by Grade, Among Those Who Experienced Natural Infection With wt RSV During the Subsequent RSV Season | Medically Attended Fever | No adverse event | 9 Participants |
| RSV ΔNS2/Δ1313/I1314L Vaccine | Number of Participants Who Had RSV-associated Symptomatic, Medically Attended Respiratory and Febrile Illness, by Grade, Among Those Who Experienced Natural Infection With wt RSV During the Subsequent RSV Season | Medically Attended URI | Grade 3 | 0 Participants |
| RSV ΔNS2/Δ1313/I1314L Vaccine | Number of Participants Who Had RSV-associated Symptomatic, Medically Attended Respiratory and Febrile Illness, by Grade, Among Those Who Experienced Natural Infection With wt RSV During the Subsequent RSV Season | Medically Attended Otitis Media | Grade 3 | 0 Participants |
| RSV ΔNS2/Δ1313/I1314L Vaccine | Number of Participants Who Had RSV-associated Symptomatic, Medically Attended Respiratory and Febrile Illness, by Grade, Among Those Who Experienced Natural Infection With wt RSV During the Subsequent RSV Season | Medically Attended Fever | Grade 3 | 0 Participants |
| RSV ΔNS2/Δ1313/I1314L Vaccine | Number of Participants Who Had RSV-associated Symptomatic, Medically Attended Respiratory and Febrile Illness, by Grade, Among Those Who Experienced Natural Infection With wt RSV During the Subsequent RSV Season | Medically Attended URI | Grade 2 | 2 Participants |
| RSV ΔNS2/Δ1313/I1314L Vaccine | Number of Participants Who Had RSV-associated Symptomatic, Medically Attended Respiratory and Febrile Illness, by Grade, Among Those Who Experienced Natural Infection With wt RSV During the Subsequent RSV Season | Medically Attended Otitis Media | Grade 4 | 0 Participants |
| RSV ΔNS2/Δ1313/I1314L Vaccine | Number of Participants Who Had RSV-associated Symptomatic, Medically Attended Respiratory and Febrile Illness, by Grade, Among Those Who Experienced Natural Infection With wt RSV During the Subsequent RSV Season | Medically Attended LRI | Grade 4 | 0 Participants |
| RSV ΔNS2/Δ1313/I1314L Vaccine | Number of Participants Who Had RSV-associated Symptomatic, Medically Attended Respiratory and Febrile Illness, by Grade, Among Those Who Experienced Natural Infection With wt RSV During the Subsequent RSV Season | Medically Attended URI | Grade 1 | 0 Participants |
| RSV ΔNS2/Δ1313/I1314L Vaccine | Number of Participants Who Had RSV-associated Symptomatic, Medically Attended Respiratory and Febrile Illness, by Grade, Among Those Who Experienced Natural Infection With wt RSV During the Subsequent RSV Season | Medically Attended URI | No adverse event | 9 Participants |
| RSV ΔNS2/Δ1313/I1314L Vaccine | Number of Participants Who Had RSV-associated Symptomatic, Medically Attended Respiratory and Febrile Illness, by Grade, Among Those Who Experienced Natural Infection With wt RSV During the Subsequent RSV Season | Medically Attended LRI | Grade 2 | 1 Participants |
| RSV ΔNS2/Δ1313/I1314L Vaccine | Number of Participants Who Had RSV-associated Symptomatic, Medically Attended Respiratory and Febrile Illness, by Grade, Among Those Who Experienced Natural Infection With wt RSV During the Subsequent RSV Season | Medically Attended Fever | Grade 4 | 0 Participants |
| RSV ΔNS2/Δ1313/I1314L Vaccine | Number of Participants Who Had RSV-associated Symptomatic, Medically Attended Respiratory and Febrile Illness, by Grade, Among Those Who Experienced Natural Infection With wt RSV During the Subsequent RSV Season | Medically Attended LRI | Grade 3 | 0 Participants |
| RSV ΔNS2/Δ1313/I1314L Vaccine | Number of Participants Who Had RSV-associated Symptomatic, Medically Attended Respiratory and Febrile Illness, by Grade, Among Those Who Experienced Natural Infection With wt RSV During the Subsequent RSV Season | Medically Attended LRI | Grade 1 | 0 Participants |
| RSV ΔNS2/Δ1313/I1314L Vaccine | Number of Participants Who Had RSV-associated Symptomatic, Medically Attended Respiratory and Febrile Illness, by Grade, Among Those Who Experienced Natural Infection With wt RSV During the Subsequent RSV Season | Medically Attended Otitis Media | No adverse event | 9 Participants |
| RSV ΔNS2/Δ1313/I1314L Vaccine | Number of Participants Who Had RSV-associated Symptomatic, Medically Attended Respiratory and Febrile Illness, by Grade, Among Those Who Experienced Natural Infection With wt RSV During the Subsequent RSV Season | Medically Attended Fever | Grade 2 | 1 Participants |
| RSV ΔNS2/Δ1313/I1314L Vaccine | Number of Participants Who Had RSV-associated Symptomatic, Medically Attended Respiratory and Febrile Illness, by Grade, Among Those Who Experienced Natural Infection With wt RSV During the Subsequent RSV Season | Medically Attended LRI | No adverse event | 10 Participants |
| RSV ΔNS2/Δ1313/I1314L Vaccine | Number of Participants Who Had RSV-associated Symptomatic, Medically Attended Respiratory and Febrile Illness, by Grade, Among Those Who Experienced Natural Infection With wt RSV During the Subsequent RSV Season | Medically Attended Otitis Media | Grade 1 | 0 Participants |
| RSV ΔNS2/Δ1313/I1314L Vaccine | Number of Participants Who Had RSV-associated Symptomatic, Medically Attended Respiratory and Febrile Illness, by Grade, Among Those Who Experienced Natural Infection With wt RSV During the Subsequent RSV Season | Medically Attended Fever | Grade 1 | 1 Participants |
| RSV 276 Vaccine | Number of Participants Who Had RSV-associated Symptomatic, Medically Attended Respiratory and Febrile Illness, by Grade, Among Those Who Experienced Natural Infection With wt RSV During the Subsequent RSV Season | Medically Attended LRI | Grade 2 | 2 Participants |
| RSV 276 Vaccine | Number of Participants Who Had RSV-associated Symptomatic, Medically Attended Respiratory and Febrile Illness, by Grade, Among Those Who Experienced Natural Infection With wt RSV During the Subsequent RSV Season | Medically Attended Fever | No adverse event | 4 Participants |
| RSV 276 Vaccine | Number of Participants Who Had RSV-associated Symptomatic, Medically Attended Respiratory and Febrile Illness, by Grade, Among Those Who Experienced Natural Infection With wt RSV During the Subsequent RSV Season | Medically Attended Fever | Grade 1 | 0 Participants |
| RSV 276 Vaccine | Number of Participants Who Had RSV-associated Symptomatic, Medically Attended Respiratory and Febrile Illness, by Grade, Among Those Who Experienced Natural Infection With wt RSV During the Subsequent RSV Season | Medically Attended Fever | Grade 2 | 0 Participants |
| RSV 276 Vaccine | Number of Participants Who Had RSV-associated Symptomatic, Medically Attended Respiratory and Febrile Illness, by Grade, Among Those Who Experienced Natural Infection With wt RSV During the Subsequent RSV Season | Medically Attended Fever | Grade 3 | 1 Participants |
| RSV 276 Vaccine | Number of Participants Who Had RSV-associated Symptomatic, Medically Attended Respiratory and Febrile Illness, by Grade, Among Those Who Experienced Natural Infection With wt RSV During the Subsequent RSV Season | Medically Attended Fever | Grade 4 | 0 Participants |
| RSV 276 Vaccine | Number of Participants Who Had RSV-associated Symptomatic, Medically Attended Respiratory and Febrile Illness, by Grade, Among Those Who Experienced Natural Infection With wt RSV During the Subsequent RSV Season | Medically Attended Otitis Media | No adverse event | 4 Participants |
| RSV 276 Vaccine | Number of Participants Who Had RSV-associated Symptomatic, Medically Attended Respiratory and Febrile Illness, by Grade, Among Those Who Experienced Natural Infection With wt RSV During the Subsequent RSV Season | Medically Attended Otitis Media | Grade 1 | 0 Participants |
| RSV 276 Vaccine | Number of Participants Who Had RSV-associated Symptomatic, Medically Attended Respiratory and Febrile Illness, by Grade, Among Those Who Experienced Natural Infection With wt RSV During the Subsequent RSV Season | Medically Attended Otitis Media | Grade 2 | 1 Participants |
| RSV 276 Vaccine | Number of Participants Who Had RSV-associated Symptomatic, Medically Attended Respiratory and Febrile Illness, by Grade, Among Those Who Experienced Natural Infection With wt RSV During the Subsequent RSV Season | Medically Attended Otitis Media | Grade 3 | 0 Participants |
| RSV 276 Vaccine | Number of Participants Who Had RSV-associated Symptomatic, Medically Attended Respiratory and Febrile Illness, by Grade, Among Those Who Experienced Natural Infection With wt RSV During the Subsequent RSV Season | Medically Attended Otitis Media | Grade 4 | 0 Participants |
| RSV 276 Vaccine | Number of Participants Who Had RSV-associated Symptomatic, Medically Attended Respiratory and Febrile Illness, by Grade, Among Those Who Experienced Natural Infection With wt RSV During the Subsequent RSV Season | Medically Attended URI | No adverse event | 2 Participants |
| RSV 276 Vaccine | Number of Participants Who Had RSV-associated Symptomatic, Medically Attended Respiratory and Febrile Illness, by Grade, Among Those Who Experienced Natural Infection With wt RSV During the Subsequent RSV Season | Medically Attended URI | Grade 1 | 0 Participants |
| RSV 276 Vaccine | Number of Participants Who Had RSV-associated Symptomatic, Medically Attended Respiratory and Febrile Illness, by Grade, Among Those Who Experienced Natural Infection With wt RSV During the Subsequent RSV Season | Medically Attended URI | Grade 2 | 3 Participants |
| RSV 276 Vaccine | Number of Participants Who Had RSV-associated Symptomatic, Medically Attended Respiratory and Febrile Illness, by Grade, Among Those Who Experienced Natural Infection With wt RSV During the Subsequent RSV Season | Medically Attended URI | Grade 3 | 0 Participants |
| RSV 276 Vaccine | Number of Participants Who Had RSV-associated Symptomatic, Medically Attended Respiratory and Febrile Illness, by Grade, Among Those Who Experienced Natural Infection With wt RSV During the Subsequent RSV Season | Medically Attended URI | Grade 4 | 0 Participants |
| RSV 276 Vaccine | Number of Participants Who Had RSV-associated Symptomatic, Medically Attended Respiratory and Febrile Illness, by Grade, Among Those Who Experienced Natural Infection With wt RSV During the Subsequent RSV Season | Medically Attended LRI | No adverse event | 3 Participants |
| RSV 276 Vaccine | Number of Participants Who Had RSV-associated Symptomatic, Medically Attended Respiratory and Febrile Illness, by Grade, Among Those Who Experienced Natural Infection With wt RSV During the Subsequent RSV Season | Medically Attended LRI | Grade 1 | 0 Participants |
| RSV 276 Vaccine | Number of Participants Who Had RSV-associated Symptomatic, Medically Attended Respiratory and Febrile Illness, by Grade, Among Those Who Experienced Natural Infection With wt RSV During the Subsequent RSV Season | Medically Attended LRI | Grade 3 | 0 Participants |
| RSV 276 Vaccine | Number of Participants Who Had RSV-associated Symptomatic, Medically Attended Respiratory and Febrile Illness, by Grade, Among Those Who Experienced Natural Infection With wt RSV During the Subsequent RSV Season | Medically Attended LRI | Grade 4 | 0 Participants |
| Placebo | Number of Participants Who Had RSV-associated Symptomatic, Medically Attended Respiratory and Febrile Illness, by Grade, Among Those Who Experienced Natural Infection With wt RSV During the Subsequent RSV Season | Medically Attended Fever | Grade 1 | 0 Participants |
| Placebo | Number of Participants Who Had RSV-associated Symptomatic, Medically Attended Respiratory and Febrile Illness, by Grade, Among Those Who Experienced Natural Infection With wt RSV During the Subsequent RSV Season | Medically Attended URI | Grade 3 | 0 Participants |
| Placebo | Number of Participants Who Had RSV-associated Symptomatic, Medically Attended Respiratory and Febrile Illness, by Grade, Among Those Who Experienced Natural Infection With wt RSV During the Subsequent RSV Season | Medically Attended Otitis Media | Grade 1 | 0 Participants |
| Placebo | Number of Participants Who Had RSV-associated Symptomatic, Medically Attended Respiratory and Febrile Illness, by Grade, Among Those Who Experienced Natural Infection With wt RSV During the Subsequent RSV Season | Medically Attended LRI | Grade 4 | 0 Participants |
| Placebo | Number of Participants Who Had RSV-associated Symptomatic, Medically Attended Respiratory and Febrile Illness, by Grade, Among Those Who Experienced Natural Infection With wt RSV During the Subsequent RSV Season | Medically Attended URI | Grade 4 | 0 Participants |
| Placebo | Number of Participants Who Had RSV-associated Symptomatic, Medically Attended Respiratory and Febrile Illness, by Grade, Among Those Who Experienced Natural Infection With wt RSV During the Subsequent RSV Season | Medically Attended Otitis Media | No adverse event | 3 Participants |
| Placebo | Number of Participants Who Had RSV-associated Symptomatic, Medically Attended Respiratory and Febrile Illness, by Grade, Among Those Who Experienced Natural Infection With wt RSV During the Subsequent RSV Season | Medically Attended LRI | Grade 3 | 0 Participants |
| Placebo | Number of Participants Who Had RSV-associated Symptomatic, Medically Attended Respiratory and Febrile Illness, by Grade, Among Those Who Experienced Natural Infection With wt RSV During the Subsequent RSV Season | Medically Attended LRI | No adverse event | 3 Participants |
| Placebo | Number of Participants Who Had RSV-associated Symptomatic, Medically Attended Respiratory and Febrile Illness, by Grade, Among Those Who Experienced Natural Infection With wt RSV During the Subsequent RSV Season | Medically Attended Fever | Grade 4 | 0 Participants |
| Placebo | Number of Participants Who Had RSV-associated Symptomatic, Medically Attended Respiratory and Febrile Illness, by Grade, Among Those Who Experienced Natural Infection With wt RSV During the Subsequent RSV Season | Medically Attended Fever | No adverse event | 4 Participants |
| Placebo | Number of Participants Who Had RSV-associated Symptomatic, Medically Attended Respiratory and Febrile Illness, by Grade, Among Those Who Experienced Natural Infection With wt RSV During the Subsequent RSV Season | Medically Attended LRI | Grade 1 | 0 Participants |
| Placebo | Number of Participants Who Had RSV-associated Symptomatic, Medically Attended Respiratory and Febrile Illness, by Grade, Among Those Who Experienced Natural Infection With wt RSV During the Subsequent RSV Season | Medically Attended Fever | Grade 3 | 0 Participants |
| Placebo | Number of Participants Who Had RSV-associated Symptomatic, Medically Attended Respiratory and Febrile Illness, by Grade, Among Those Who Experienced Natural Infection With wt RSV During the Subsequent RSV Season | Medically Attended URI | No adverse event | 3 Participants |
| Placebo | Number of Participants Who Had RSV-associated Symptomatic, Medically Attended Respiratory and Febrile Illness, by Grade, Among Those Who Experienced Natural Infection With wt RSV During the Subsequent RSV Season | Medically Attended Otitis Media | Grade 4 | 0 Participants |
| Placebo | Number of Participants Who Had RSV-associated Symptomatic, Medically Attended Respiratory and Febrile Illness, by Grade, Among Those Who Experienced Natural Infection With wt RSV During the Subsequent RSV Season | Medically Attended Fever | Grade 2 | 0 Participants |
| Placebo | Number of Participants Who Had RSV-associated Symptomatic, Medically Attended Respiratory and Febrile Illness, by Grade, Among Those Who Experienced Natural Infection With wt RSV During the Subsequent RSV Season | Medically Attended URI | Grade 1 | 0 Participants |
| Placebo | Number of Participants Who Had RSV-associated Symptomatic, Medically Attended Respiratory and Febrile Illness, by Grade, Among Those Who Experienced Natural Infection With wt RSV During the Subsequent RSV Season | Medically Attended Otitis Media | Grade 3 | 0 Participants |
| Placebo | Number of Participants Who Had RSV-associated Symptomatic, Medically Attended Respiratory and Febrile Illness, by Grade, Among Those Who Experienced Natural Infection With wt RSV During the Subsequent RSV Season | Medically Attended LRI | Grade 2 | 1 Participants |
| Placebo | Number of Participants Who Had RSV-associated Symptomatic, Medically Attended Respiratory and Febrile Illness, by Grade, Among Those Who Experienced Natural Infection With wt RSV During the Subsequent RSV Season | Medically Attended URI | Grade 2 | 1 Participants |
| Placebo | Number of Participants Who Had RSV-associated Symptomatic, Medically Attended Respiratory and Febrile Illness, by Grade, Among Those Who Experienced Natural Infection With wt RSV During the Subsequent RSV Season | Medically Attended Otitis Media | Grade 2 | 1 Participants |